PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026Blood Cancer Discovery0 citations

Models, Models, Everywhere: But Which One Should Guide Care?

View Full Paper
CLCurtis A. LachowiezSLSanam Loghavi

Key Points

  • To develop a therapy-specific prognostic model that integrates mutational and cytogenetic features for acute myeloid leukemia.
  • Developed a prognostic model using mutational and cytogenetic data
  • Evaluated survival outcomes in patients treated with venetoclax-based regimens
  • Compared findings with existing prognostic models
  • The model effectively stratified patients based on risk of survival
  • Integration of mutational and cytogenetic features improved risk assessment
  • Findings provide a framework for clinical decision-making

Abstract

Summary: Drekolias and colleagues report a therapy-specific prognostic model integrating mutational and cytogenetic features to risk-stratify survival in patients with acute myeloid leukemia treated with venetoclax-based regimens, providing a clinically relevant framework amid a rapidly expanding landscape of competing models. See related article by Drekolias et al., p. XX .

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lachowiez et al. (2026) studied this question.

synapsesocial.com/papers/69cd7b695652765b073a9656https://doi.org/10.1158/2643-3230.bcd-26-0055
Ask AI
Helpful
Bookmark
Share
View Full Paper